Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
WALTHAM, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 8th Annual Biotech Showcase™ Conference on Monday, January 11, 2016 at 11:30 AM PST at the Parc 55 Hotel in San Francisco, CA.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be available on Histogenics’ website for 30 days following the conference.
The Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its eighth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
